within Pharmacolibrary.Drugs.ATC.M;

model M03BA53
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0018333333333333333,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.0006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007500000000000001,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Methocarbamol is a centrally acting muscle relaxant used for the relief of discomfort associated with acute, painful musculoskeletal conditions. The combination with other agents excluding psycholeptics is intended for enhanced symptomatic relief. Methocarbamol combinations are generally used short-term in adults and are approved in several countries, though specific combination products may differ in approval status.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult (age 18â€“65), both sexes, no specific comorbidities, for an oral formulation of methocarbamol as no published PK data specific to combinations (excl. psycholeptics) were found.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M03BA53;
